A Phase II Randomized Double-Masked Trial of Pegaptanib, an Anti–Vascular Endothelial Growth Factor Aptamer, for Diabetic Macular Edema
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
Vascular Endothelial Growth Factor Is a Secreted Angiogenic Mitogen
Leung, D. W., Cachianes, G., Kuang, W.-J., Goeddel, D. V., & Ferrara, N. (1989) · Science · doi:10.1126/science.2479986 · Cited by 4,986
Aiello, L. P., Avery, R. L., Arrigg, P. G., Keyt, B. A., Jampel, H. D., Shah, S. T., Pasquale, L. R., Thieme, H., Iwamoto, M. A., Park, J. E., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199412013312203 · Cited by 3,793
Pegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337
Self-citationKlein, R. (1984) · Archives of Ophthalmology · doi:10.1001/archopht.1984.01040030398010 · Cited by 1,885
Klein, R. (1984) · Archives of Ophthalmology · doi:10.1001/archopht.1984.01040030405011 · Cited by 1,477
Klein, R., Klein, B. E. K., Moss, S. E., & Linton, K. L. P. (1992) · Ophthalmology · doi:10.1016/s0161-6420(92)32011-1 · Cited by 1,340
Adamis, A. P., Miller, J. W., Bernal, M.-T., D'Amico, D. J., Folkman, J., Yeo, T.-K., & Yeo, K.-T. (1994) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(14)75794-0 · Cited by 1,296
Aiello, L. P., Pierce, E. A., Foley, E. D., Takagi, H., Chen, H., Riddle, L., Ferrara, N., King, G. L., & Smith, L. E. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.23.10457 · Cited by 1,260
Cited by
Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease
Ng, E. W. M., Shima, D. T., Calias, P., Cunningham, E. T., Guyer, D. R., & Adamis, A. P. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1955 · Cited by 1,588
Management of Diabetic Retinopathy: A Systematic Review
Mohamed, Q., Gillies, M. C., & Wong, T. Y. (2007) · JAMA · doi:10.1001/jama.298.8.902 · Cited by 891
Intravitreal Bevacizumab (Avastin) in the Treatment of Proliferative Diabetic Retinopathy
Avery, R. L., Pearlman, J., Pieramici, D. J., Rabena, M. D., Castellarin, A. A., Nasir, M. A., Giust, M. J., Wendel, R., & Patel, A. (2006) · Ophthalmology · doi:10.1016/j.ophtha.2006.05.064 · Cited by 799
Vascular endothelial growth factor in eye disease
Penn, J. S., Madan, A., Caldwell, R. B., Bartoli, M., Caldwell, R. W., & Hartnett, M. E. (2008) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2008.05.001 · Cited by 762
Safety and Efficacy of Ranibizumab in Diabetic Macular Edema (RESOLVE Study)
Massin, P., Bandello, F., Garweg, J. G., Hansen, L. L., Harding, S. P., Larsen, M., Mitchell, P., Sharp, D., Wolf-Schnurrbusch, U. E. K., Gekkieva, M., et al. (2010) · Diabetes Care · doi:10.2337/dc10-0493 · Cited by 720
Current approaches in SELEX: An update to aptamer selection technology
Darmostuk, M., Rimpelova, S., Gbelcova, H., & Ruml, T. (2015) · Biotechnology Advances · doi:10.1016/j.biotechadv.2015.02.008 · Cited by 702
(2007) · Endocrine Practice · doi:10.4158/ep.13.s1.1 · Cited by 699
Diabetic Macular Edema: Pathogenesis and Treatment
Bhagat, N., Grigorian, R. A., Tutela, A., & Zarbin, M. A. (2009) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2008.10.001 · Cited by 571
(2008) · Ophthalmology · doi:10.1016/j.ophtha.2008.06.015 · Cited by 548
Kaur, C., Foulds, W. S., & Ling, E. A. (2008) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2008.09.003 · Cited by 470
Wu, L., Martínez-Castellanos, M. A., Quiroz-Mercado, H., Arevalo, J. F., Berrocal, M. H., Farah, M. E., Maia, M., Roca, J. A., Rodriguez, F. J., & for the Pan American Collaborative Retina Group (PACORES) (2007) · Graefe's Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-007-0660-z · Cited by 456
“Recently pegaptanib sodium (Macugen®, Eyetech, NY, NY), an aptamer against VEGF165, has been shown to be beneficial in the treatment of CNV secondary to age-related macular degeneration (ARMD) and DME [5, 6].”
BackgroundPathophysiology of Diabetic Retinopathy
Tarr, J. M., Kaul, K., Chopra, M., Kohner, E. M., & Chibber, R. (2013) · ISRN Ophthalmology · doi:10.1155/2013/343560 · Cited by 455
INTRAVITREAL BEVACIZUMAB (AVASTIN) THERAPY FOR PERSISTENT DIFFUSE DIABETIC MACULAR EDEMA
HARITOGLOU, C., KOOK, D., NEUBAUER, A., WOLF, A., PRIGLINGER, S., STRAUSS, R., GANDORFER, A., ULBIG, M., & KAMPIK, A. (2006) · Retina · doi:10.1097/01.iae.0000247165.38655.bf · Cited by 453
A Phase II Randomized Clinical Trial of Intravitreal Bevacizumab for Diabetic Macular Edema
(2007) · Ophthalmology · doi:10.1016/j.ophtha.2007.05.062 · Cited by 451
GILLIES, M., SUTTER, F., SIMPSON, J., LARSSON, J., ALI, H., & ZHU, M. (2006) · Ophthalmology · doi:10.1016/j.ophtha.2006.02.065 · Cited by 425
Lee, J. F., Stovall, G. M., & Ellington, A. D. (2006) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2006.03.015 · Cited by 398
Microvascular lesions of diabetic retinopathy: clues towards understanding pathogenesis?
Curtis, T. M., Gardiner, T. A., & Stitt, A. W. (2009) · Eye · doi:10.1038/eye.2009.108 · Cited by 393
One-Year Outcomes of the DA VINCI Study of VEGF Trap-Eye in Eyes with Diabetic Macular Edema
Do, D. V., Nguyen, Q. D., Boyer, D., Schmidt-Erfurth, U., Brown, D. M., Vitti, R., Berliner, A. J., Gao, B., Zeitz, O., Ruckert, R., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.02.010 · Cited by 385
Chiu, S. J., Allingham, M. J., Mettu, P. S., Cousins, S. W., Izatt, J. A., & Farsiu, S. (2015) · Biomedical Optics Express · doi:10.1364/boe.6.001172 · Cited by 377
Ocular complications of diabetes mellitus
Sayin, N. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i1.92 · Cited by 358
Vascular Endothelial Growth Factor Is a Critical Stimulus for Diabetic Macular Edema
Nguyen, Q. D., Tatlipinar, S., Shah, S. M., Haller, J. A., Quinlan, E., Sung, J., Zimmer-Galler, I., Do, D. V., & Campochiaro, P. A. (2006) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2006.06.068 · Cited by 351
Primary Intravitreal Bevacizumab (Avastin) for Diabetic Macular Edema
Arevalo, J. F., Fromow-Guerra, J., Quiroz-Mercado, H., Sanchez, J. G., Wu, L., Maia, M., Berrocal, M. H., Solis-Vivanco, A., & Farah, M. E. (2007) · Ophthalmology · doi:10.1016/j.ophtha.2006.12.028 · Cited by 335
Immunological mechanisms in the pathogenesis of diabetic retinopathy
Adamis, A. P., & Berman, A. J. (2008) · Seminars in Immunopathology · doi:10.1007/s00281-008-0111-x · Cited by 322
Systemic and Ocular Safety of Intravitreal Anti-VEGF Therapies for Ocular Neovascular Disease
Tolentino, M. (2011) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2010.08.006 · Cited by 304
Chun, D. W., Heier, J. S., Topping, T. M., Duker, J. S., & Bankert, J. M. (2006) · Ophthalmology · doi:10.1016/j.ophtha.2006.04.033 · Cited by 295
Gupta, N., Mansoor, S., Sharma, A., Sapkal, A., Sheth, J., Falatoonzadeh, P., Kuppermann, B., & Kenney, M. (2013) · The Open Ophthalmology Journal · doi:10.2174/1874364101307010004 · Cited by 285
Anti-vascular endothelial growth factor therapy for ocular neovascular disease
Andreoli, C. M., & Miller, J. W. (2007) · Current Opinion in Ophthalmology · doi:10.1097/icu.0b013e3282f0ca54 · Cited by 274
A review of clinical trials of anti-VEGF agents for diabetic retinopathy
Nicholson, B. P., & Schachat, A. P. (2010) · Graefe's Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-010-1315-z · Cited by 272
Diabetic retinopathy and systemic vascular complications
Cheung, N., & Wong, T. Y. (2008) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2007.12.001 · Cited by 269
Report from the NEI/FDA Ophthalmic Clinical Trial Design and Endpoints Symposium *
Csaky, K. G., Richman, E. A., & Ferris, F. L. (2008) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.07-1132 · Cited by 265
Virgili, G., Menchini, F., Casazza, G., Hogg, R., Das, R. R., Wang, X., & Michelessi, M. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008081.pub3 · Cited by 265
Molecular mechanism of VEGF and its role in pathological angiogenesis
Ahmad, A., & Nawaz, M. I. (2022) · Journal of Cellular Biochemistry · doi:10.1002/jcb.30344 · Cited by 260
Therapeutic RNA aptamers in clinical trials
Sundaram, P., Kurniawan, H., Byrne, M. E., & Wower, J. (2013) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2012.10.014 · Cited by 259
INTRAVITREAL BEVACIZUMAB (AVASTIN) FOR PERSISTENT NEW VESSELS IN DIABETIC RETINOPATHY (IBEPE STUDY)
JORGE, R., COSTA, R. A., CALUCCI, D., CINTRA, L. P., & SCOTT, I. U. (2006) · Retina · doi:10.1097/01.iae.0000246884.76018.63 · Cited by 258
INTRAVITREAL INJECTION OF THERAPEUTIC AGENTS
PEYMAN, G. A., LAD, E. M., & MOSHFEGHI, D. M. (2009) · Retina · doi:10.1097/iae.0b013e3181a94f01 · Cited by 255
Kollias, A. N., & Ulbig, M. W. (2010) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2010.0075 · Cited by 253
Vascular endothelial growth factor and diabetic complications
WIROSTKO, B., WONG, T., & SIMO, R. (2008) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2008.09.002 · Cited by 241
Diabetic macular edema: Evidence-based management
Stewart, M., Browning, D., & Lee, C. (2018) · Indian Journal of Ophthalmology · doi:10.4103/ijo.ijo_1240_18 · Cited by 237
The Evolving Treatment of Diabetic Retinopathy
Mansour, S. E., Browning, D. J., Wong, K., Flynn Jr, H. W., & Bhavsar, A. R. (2020) · Clinical Ophthalmology · doi:10.2147/opth.s236637 · Cited by 229
Anti-vascular endothelial growth factor therapy for diabetic macular edema
Boyer, D. S., Hopkins, J. J., Sorof, J., & Ehrlich, J. S. (2013) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018813512360 · Cited by 193
“Bevacizumab is neither designed nor manufactured for use in the eye; however, it is used off label, by intravitreal injection, for the treatment of intraocular vascular diseases, including wet AMD, RVO, and DME [Stewart, 2012].”
BackgroundResultInfluentialPang, Y., Rong, Z., Wang, J., Xiao, R., & Wang, S. (2015) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2014.10.052 · Cited by 186
Therapeutic Applications of DNA and RNA Aptamers
Thiel, K. W., & Giangrande, P. H. (2009) · Oligonucleotides · doi:10.1089/oli.2009.0199 · Cited by 173
“In addition to AMD, a Phase II clinical trial also investigated pegaptanib in the treatment of diabetic retinopathy and found improved vision and reduced macular edema (Cunningham et al., 2005).”
Zhang, X., Bao, S., Lai, D., Rapkins, R. W., & Gillies, M. C. (2008) · Diabetes · doi:10.2337/db07-0982 · Cited by 159
“AMD, age-related macular degeneration; AEC, 3-amino-9-ethylcarbazole chromogen; BRB, blood-retinal barrier; DAB, diaminobenzidine; DR, diabetic retinopathy; FLK, fetal liver kinase; FLT, fms-like tyrosine kinase; IAU, image arbitrary unit; IPP, Image-Pro Plus; IVTA, intravitreal injection of triamcinolone acetonide; P…”
BackgroundInfluentialINCIDENCE OF ACUTE ONSET ENDOPHTHALMITIS FOLLOWING INTRAVITREAL BEVACIZUMAB (AVASTIN) INJECTION
MASON, J. O., WHITE, M. F., FEIST, R. M., THOMLEY, M. L., ALBERT, M. A., PERSAUD, T. O., YUNKER, J. J., & VAIL, R. S. (2008) · Retina · doi:10.1097/iae.0b013e3181633fee · Cited by 158
Microvascular complications and diabetic retinopathy: recent advances and future implications
Barot, M., Gokulgandhi, M. R., Patel, S., & Mitra, A. K. (2013) · Future Medicinal Chemistry · doi:10.4155/fmc.12.206 · Cited by 92
Muolokwu, C. E., Chaulagain, B., Gothwal, A., Mahanta, A. K., Tagoe, B., Lamsal, B., & Singh, J. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1405423 · Cited by 42
Metadata
- Venue
- Ophthalmology
- Publisher
- Elsevier BV
- Published
- 2005-10
- Volume
- 112
- Issue
- 10
- Pages
- 1747-1757
- ISSN
- 0161-6420 (ISSN-L)
- OpenAlex
- W1526282761
- Cited by
- 594
- References
- 23
- FWCI
- 48.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.